Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Free Cash Flow (2021 - 2025)

Kezar Life Sciences' Free Cash Flow history spans 5 years, with the latest figure at -$9.8 million for Q3 2025.

  • For Q3 2025, Free Cash Flow rose 43.87% year-over-year to -$9.8 million; the TTM value through Sep 2025 reached -$56.7 million, up 24.03%, while the annual FY2024 figure was -$74.2 million, 9.07% up from the prior year.
  • Free Cash Flow for Q3 2025 was -$9.8 million at Kezar Life Sciences, up from -$12.8 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$8.4 million in Q1 2021 and bottomed at -$23.0 million in Q2 2023.
  • The 5-year median for Free Cash Flow is -$16.8 million (2024), against an average of -$15.7 million.
  • The largest annual shift saw Free Cash Flow plummeted 71.51% in 2023 before it soared 43.87% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$11.3 million in 2021, then fell by 29.53% to -$14.7 million in 2022, then fell by 16.85% to -$17.2 million in 2023, then increased by 1.95% to -$16.8 million in 2024, then soared by 41.61% to -$9.8 million in 2025.
  • Per Business Quant, the three most recent readings for KZR's Free Cash Flow are -$9.8 million (Q3 2025), -$12.8 million (Q2 2025), and -$17.2 million (Q1 2025).